Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical stage biopharmaceutical company developing novel therapeutics for orphan patient populations with B-cell lymphomas and autoimmune diseases, today announced the addition of three new management team members to support the Company’s progress in its development pipeline. The Company has appointed Kathryn Haviland, Vice President Rare Diseases; Joseph Lobacki, General Manager of Oncology; and Walter Strapps, Ph.D., Executive Director of RNA Therapeutics.
Help employers find you! Check out all the jobs and post your resume.
